This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Mori et al. (2009) · Phytotherapy Research
- Population
- 30 Japanese adults ages 50 to 80 with mild cognitive impairment; 29 were included in the statistical analysis
- Intervention
- Lion's mane fruiting-body tablets providing about 3 g/day for 16 weeks
- Comparator
- Matched placebo tablets for the same 16-week period, followed by a 4-week washout
- Finding
- The intervention group outperformed placebo on the study's cognitive scale across the trial, but the signal weakened after treatment stopped.
preliminary This was a better design than most supplement studies, but it was still small, used a custom outcome scale, and involved substantial manufacturer participation.
Mori et al. (2009), Methods and Figure 1
Key Numbers
The most useful numbers from the full paper
29/30
Per-protocol analysis
1 intervention dropout was excluded rather than carried forward
22-25/30
Entry score band
A narrow mild-impairment range on the trial's 30-point screen
3 points
Notable-improvement threshold
The paper treated a 3-point gain as meaningfully better
71.4%
Notably improved
10/14 reached that benchmark vs 1/15 on placebo
p < .001
Overall signal
Between-group, period, and interaction terms
The key benchmark is the authors' own threshold: a 3-point gain on this 30-point scale counted as 'notably improved.' That makes the week-16 split more useful than a vague claim of statistical significance alone.
Mori et al. (2009), Figure 1, Figure 2, and Results
- Weeks -2 to 0
Preliminary screening
- Participants had to score 22 to 25 on the investigators' 30-point cognitive function scale based on HDS-R.
- The paper says the groups did not differ in age or preliminary cognitive scores before treatment started.
- Weeks 0 to 16
Randomized double-blind treatment
- 30 participants were randomized to lion's mane or placebo tablets, 15 per group.
- The active tablets contained 96% Yamabushitake powder, and the placebo used cornstarch and lactose in same-shaped tablets.
- Weeks 8, 12, 16
Primary cognitive readouts
- The lion's mane group scored significantly higher than placebo at all three on-treatment checkpoints.
- The repeated-measures model found p < 0.001 for between-group, between-period, and interaction terms.
- Weeks 16 to 20
Washout after stopping
- The intervention group's score fell significantly during the 4-week follow-up after intake stopped.
- That makes this look more like a reversible support signal than a durable disease-modifying effect.
Mori et al. (2009), Methods and Figure 1
What This Trial Really Shows
This is one of the better-known lion's mane human studies for a reason. It was randomized, double-blind, and placebo-controlled, which already puts it above the usual supplement-testimonial tier.
But the stronger read is not "lion's mane is proven for cognition." The stronger read is narrower: a small but real randomized signal appeared in adults with mild cognitive impairment, using a defined fruiting-body tablet over 16 weeks.
That is valuable. It is not the same thing as having a large, independently replicated dementia trial.
Why The Numbers Matter
The paper gives you more useful context than the abstract alone.
- Participants were not just vaguely forgetful; they entered in a narrow 22-to-25 range on the study's 30-point screen, which puts this trial in early decline rather than advanced dementia.
- Within this paper, the authors treated a 3-point increase as "notably improved" and a 2-point increase as "improved."
- By week 16, 10 of 14 analyzed participants in the intervention group met the notable-improvement threshold, compared with 1 of 15 on placebo.
- Another 3 of 14 in the intervention group and 1 of 15 on placebo met the 2-point improvement threshold.
That makes the signal easier to interpret than a bare p-value. This was not just noise on a long scale with unclear meaning. The categories are still the paper's own framework, but they are much more informative than abstract language that only says the result was "significant."
The other key benchmark is durability. The intervention group's score dropped significantly during the 4-week washout, even though it was still above placebo. That matters because it weakens the popular story that lion's mane simply "fixes" cognition once you start taking it.
Methods Audit
Methods Audit
Where the design is solid and where it still leaks uncertainty
Randomized and double-blind: yes
The paper describes a randomized, double-blind, placebo-controlled parallel-group trial with same-shaped placebo tablets.
Randomization details: thin
The paper says subjects were randomized, but it does not explain sequence generation or allocation concealment.
Analysis population: not full intention-to-treat
One intervention participant withdrew after 4 weeks and was excluded from the statistical analysis, leaving 29 analyzed participants.
Outcome measurement: useful but custom
The primary endpoint was a 30-point investigator scale based on HDS-R plus a drawing task, not a more universally familiar cognition battery.
Manufacturer involvement: substantial
Four of the five authors were affiliated with Hokuto Corporation, which cultured the mushroom used in the intervention tablets.
Mori et al. (2009), Methods, Table 1, and author affiliations
How To Situate This Study In The Literature
This paper is important partly because it was early.
Mori 2009 appears to be one of the earliest randomized patient trials of lion's mane in a cognitively impaired population. Later human work broadened in two directions:
- into different populations, like healthy younger adults and healthy older adults
- into different formulations, like erinacine-enriched mycelia in mild Alzheimer's disease
That matters because later positive studies do not automatically count as direct replication of this exact design. A fruiting-body tablet in adults with mild cognitive impairment is not the same intervention or population as erinacine-enriched mycelia in mild Alzheimer's disease.
So the fairest summary is:
- the broader human literature did not stop with Mori 2009
- direct replication of this exact setup still looks limited
Important: Later positive lion's mane papers help the field, but they do not count as direct one-for-one replication unless they test a similar fruiting-body product in a similar mild-cognitive-impairment population.
Most Defensible Claims
Most Defensible Claims
Claims a careful reader could actually cite from this page
This was a real randomized, double-blind, placebo-controlled lion's mane trial
That alone makes it stronger than most consumer-facing lion's mane evidence.
The intervention group showed a better cognitive trajectory than placebo over 16 weeks
The repeated-measures analysis found p < 0.001 for between-group, period, and interaction effects.
The signal was not fully durable after stopping treatment
Scores fell significantly during the 4-week washout, which argues against overselling permanence.
The study does not prove lion's mane prevents dementia or Alzheimer's disease
The sample was small, the endpoint was custom, and the population had mild impairment rather than established dementia.
Mori et al. (2009), Figure 1 and Discussion
Reasons This Study Might Be Wrong
Skeptical Read
The strongest reasons not to over-update on this trial
The sample was tiny
A 29-person analyzed dataset can generate unstable estimates even when the design is randomized and blinded.
The endpoint was not a widely standard modern dementia battery
The modified HDS-R based scale may have been appropriate for the study, but it still limits cross-trial comparability.
The washout cut against a durable-benefit story
The intervention signal weakened after treatment stopped, which suggests a reversible effect or a less robust effect than headlines imply.
Corporate involvement was built into the study
Hokuto Corporation authors helped run the trial and supplied the mushroom used in the active tablets.
One stomach-related dropout still matters
Seven of 14 intervention participants and six of 15 placebo participants reported mild stomach discomfort or diarrhea, which argues against a clear lion's-mane-specific GI signal. But one intervention participant still left the trial because of stomach discomfort.
Mori et al. (2009), author affiliations, Results, and Table 3
What Happened Next
- 2009
Mori established an early patient RCT signal
- This paper gave lion's mane something unusually valuable for a supplement topic: a randomized patient trial rather than just mechanism or animal work.
- Its main weakness was scale, not total lack of experimental discipline.
- 2020
Li et al. moved the field into mild Alzheimer's disease
- A 49-week double-blind placebo-controlled pilot of erinacine A-enriched Hericium mycelia in mild Alzheimer's disease reported better MMSE, CASI, and IADL outcomes in the intervention group.
- That was a different population and formulation, so it extends the field more than it directly replicates Mori.
- 2023
Docherty et al. widened the human work into healthy adults
- A placebo-controlled pilot in healthy young adults found faster Stroop performance after an acute dose, but only a trend toward lower stress after 28 days.
- That suggests lion's mane effects may depend strongly on who is taking it and what is being measured.
- 2025
Menon et al. reviewed the field and still called it preliminary
- The 2025 review identified five randomized controlled trials overall, but emphasized small samples, mixed populations, and varied formulations.
- That means Mori remains important historically, but not decisive on its own.
Mori et al. (2009), full paper; Li et al. (2020), PMID 32581767; Docherty et al. (2023), PMID 38004235; Menon et al. (2025), PMID 40959699
Important: These later studies widen the field, but they should not be treated as direct replication of Mori's fruiting-body mild-cognitive-impairment trial.
Related follow-up sources: Li et al. 2020 (PMID 32581767), Docherty et al. 2023 (PMID 38004235), and Menon et al. 2025 (PMID 40959699).
Funding And Conflicts
This is one of the more important things the abstract does not tell you clearly.
The paper does not include a dedicated funding or conflict-of-interest section. But four of the five authors were affiliated with Hokuto Corporation's Mushroom Laboratory, and the mushroom used in the intervention tablets was cultured by Hokuto Corporation in its facilities.
That does not invalidate the result. It does mean the reader should treat independence as weak and replication as especially important.
Rethink Takeaway
The best way to read this study is as a meaningful but not decisive lion's mane cognition trial.
It gives you a real randomized signal in adults with mild cognitive impairment, and that already makes it much stronger than most mushroom-content claims on the internet. But it is still a small study, uses a custom outcome scale, includes manufacturer involvement, and loses some force when the washout period is taken seriously.
If you want the strongest defensible sentence, it is this: lion's mane has at least one small randomized trial in mild cognitive impairment showing a better cognitive trajectory than placebo during treatment, but the result is not yet strong enough to settle the case.
Read the original research
Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.
Phytotherapy research : PTR, 23(3), 367-72
Citation
Mori, Koichiro; Inatomi, Satoshi; Ouchi, Kenzi; Azumi, Yoshihito; Tuchida, Takashi. (2009). Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial.. Phytotherapy research : PTR, 23(3), 367-72. https://doi.org/10.1002/ptr.2634